Status:

UNKNOWN

Angiotensin Metabolite Profile After Subarachnoid Hemorrhage

Lead Sponsor:

Dr. Roman Ullrich

Collaborating Sponsors:

Austrian Science Fund (FWF)

Conditions:

Subarachnoid Hemorrhage, Aneurysmal

Eligibility:

All Genders

18-85 years

Brief Summary

The outcome of subarchnoid hemorrhage depends on the severity of the bleeding and the development of secondary neurologic deficits caused by cerebral vasospasm. The primary endpoint is a comparison of...

Detailed Description

Wider research context. The clinical course and neurological outcome of patients with subarachnoid hemorrhage following rupture of an intracranial aneurysm depend on surgical repair of the ruptured an...

Eligibility Criteria

Inclusion

  • Patients with a diagnosis of subarachnoid hemorrhage because of aneurysmal rupture admitted to the ICU
  • Invasive monitoring of arterial blood pressure

Exclusion

  • Patients who decline study participation
  • Brain stem death
  • Chronic renal impairment with creatinine \> 2mg/dL or hemodialysis
  • Chronic liver failure of Child Pugh class C or higher
  • Chronic heart failure
  • Hormone producing neuroendocrine tumor
  • Sarcoidosis
  • Pregnancy
  • Planned transfer to another hospital shortly after aneurysm repair

Key Trial Info

Start Date :

March 1 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

February 1 2025

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT05222542

Start Date

March 1 2022

End Date

February 1 2025

Last Update

March 2 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Medical University of Vienna

Vienna, Austria, A-1090